Since its establishment in 1991, IMS Health Hungary has achieved the position of a trusted advisor and leader in providing insights into the pharmaceutical market. IMS Health Hungary has one of the most comprehensive offering portfolios in the region, with solutions for the life sciences industry including prescription data, sell-out services and patient level analytics.
In 2008, IMS Health Hungary made a significant investment to deliver more accurate data for measuring final drug consumption levels and introduced a sell-out offering.
Since 2013, as a result of further developments in the utilization of longitudinal patient level data, IMS Health Hungary has supported clients with a deep understanding of patient dynamics to identify appropriate patient segments and tailor strategic decisions. Anonymized longitudinal patient level information provides a powerful patient lens to drive focus and alignment across business; deepening the understanding of critical patient, physician and payer dynamics.
For over two decades IMS Health Hungary has been monitoring the changes and development of the national market. In 2012, the Hungarian pharmaceutical market reached €2.1 billion (retail and hospital), contracting by close to 3 %, as a result of austerity measures. Currently 412 manufacturer groups operate in the Hungarian pharmaceutical market, with 10 corporations, including the two largest local manufacturers EGIS and Gedeon Richter, accounting for 56% of the total sales value. Generics are dominating the market with close to a 60% share of volume in 2012, while original products still hold 53% of the pharmaceutical market in value. The top therapy areas in 2012 were antineoplastic and cardiovascular.
Contact
IMS Health Hungary
Rumbach Sebestyén utca 19-21.
Budapest 1075, Hungary
Tel: +36 1 883 9700
Fax: +36 1 883 9799
IMS is a strong brand name when it comes to pharma and healthcare information worldwide. Can you please elaborate on the particularities that set the Hungarian pharmaceutical market apart from…
You founded HYD almost 20 years ago, in 1992. Can you first explain to our readers why you made the switch from doing research at the Hungarian Institute of Oncology…
Hungary has been recognized as one of the largest pharmaceutical and healthcare markets in Central and Eastern Europe, and can obviously not be ignored by Roche. First of all, can…
You took over as GM back in 2008. No doubt that this was a challenging time to run a business, in particular in view of the external economic environment. Can…
The Hungarian pharmaceutical environment has been undergoing a turbulent time recently, with many new measures being implement by the Government. What are your observations, and how do you expect companies…
Assign Group started in 2002 as a small local CRO company founded in Austria; monitoring and doing minor project management only. Why was Austria chosen as the headquarters? First, it…
With approximately $90 billion flowing into the country (according to the Hungarian Investment and Trade Agency) since it abolished its centrally planned economy and transformed into an open, pro-business economy…
Taking a look at the voices of the pharmaceutical industry in Hungary, we see AIPM and MAYGOSZ as the 2 key associations. And while MAGYOSZ already represents many generic players……
IMS is a strong brand name when it comes to pharma and healthcare information worldwide. Can you please elaborate on the particularities that set the Hungarian pharmaceutical market apart from…
The Hungarian pharmaceutical environment has been undergoing many changes recently, such as a sales tax increase to 20%. Do you feel this is a climate of threat to MNCs in…
Hungary is one of the largest pharmaceutical markets in the region, and has been used by Janssen-Cilag as a hub. Can you elaborate on how important Hungary is for Janssen-Cilag…
Talking to Cegedim means talking to one of the experts in local market knowledge. Can you tell our readers from your point of view what really distinguishes Hungary from other…
Looking at Boehringer Ingelheim (BI) in Hungary, at first glance we see a company with a presence of already 20 years, which basically means an entry into this market right…
See our Cookie Privacy Policy Here
